1-12 of 12
dasatinib
Close
Sort by
Journal Articles

A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul
Journal: Blood Advances
Blood Adv (2021) 5 (14): 2925–2934.
https://doi.org/10.1182/bloodadvances.2020003759
Published: 2021
Includes: Supplemental data
Journal Articles

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clinical Trials & Observations
Richard E. Clark, Jane F. Apperley, Mhairi Copland, Silvia Cicconi
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1102–1109.
https://doi.org/10.1182/bloodadvances.2020003570
Published: 2021
Includes: Supplemental data
Journal Articles

Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion

Clinical Trials & Observations
Shaimaa S. Eissa, Michael R. Clay, Teresa Santiago, Gang Wu, Lu Wang, Barry L. Shulkin, Jennifer Picarsic, Kim E. Nichols, Patrick K. Campbell
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2991–2995.
https://doi.org/10.1182/bloodadvances.2020001890
Published: 2020
Journal Articles

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

Clinical Trials & Observations
Claudia Vener, Rita Banzi, Federico Ambrogi, Annalisa Ferrero, Giuseppe Saglio, Gabriella Pravettoni, Milena Sant
Journal: Blood Advances
Blood Adv (2020) 4 (12): 2723–2735.
https://doi.org/10.1182/bloodadvances.2019001329
Published: 2020
Includes: Supplemental data
Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Clinical Trials & Observations
Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2020) 4 (4): 696–705.
https://doi.org/10.1182/bloodadvances.2019000492
Published: 2020
Journal Articles

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

Clinical Trials & Observations
Chihiro Yamamoto, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Miyuki Sugimoto, Yuko Ishihara, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Shin-ichiro Fujiwara, Masuzu Ueda, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3266–3277.
https://doi.org/10.1182/bloodadvances.2019000745
Published: 2019
Includes: Supplemental data
Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Clinical Trials & Observations
Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2019) 3 (6): 851–861.
https://doi.org/10.1182/bloodadvances.2018025874
Published: 2019
Includes: Supplemental data
Journal Articles

Pharmacologic control of CAR-T cell function using dasatinib

Evan W. Weber, Rachel C. Lynn, Elena Sotillo, John Lattin, Peng Xu, Crystal L. Mackall
Journal: Blood Advances
Blood Adv (2019) 3 (5): 711–717.
https://doi.org/10.1182/bloodadvances.2018028720
Published: 2019
Includes: Supplemental data
Journal Articles

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1 + BCP-ALL

Eleanor R. C. Fiedler, Arjun Bhutkar, Emily Lawler, Rana Besada, Michael T. Hemann
Journal: Blood Advances
Blood Adv (2018) 2 (11): 1229–1242.
https://doi.org/10.1182/bloodadvances.2017015610
Published: 2018
Includes: Supplemental data
Journal Articles

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

Kathryn G. Roberts, Yung-Li Yang, Debbie Payne-Turner, Wenwei Lin, Jacob K. Files, Kirsten Dickerson, Zhaohui Gu, Jack Taunton, Laura J. Janke, Taosheng Chen, Mignon L. Loh, Stephen P. Hunger, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2017) 1 (20): 1657–1671.
https://doi.org/10.1182/bloodadvances.2017011296
Published: 2017
Includes: Supplemental data
Journal Articles

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Clinical Trials & Observations
Lucy C. Fox, Katherine D. Cummins, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Journal: Blood Advances
Blood Adv (2017) 1 (13): 802–811.
https://doi.org/10.1182/bloodadvances.2016003889
Published: 2017
Journal Articles

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Clinical Trials & Observations
Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2016) 1 (3): 250–259.
https://doi.org/10.1182/bloodadvances.2016001495
Published: 2016
Includes: Supplemental data